Novavax and its partner Serum Institute of India (SII) have obtained Emergency Use Listing (EUL) from the World Health Organization (WHO) for the former’s recombinant nanoparticle protein-based Covid-19 vaccine with Matrix-M adjuvant, NVX-CoV2373.

The shot is indicated for active immunisation to prevent Covid-19 in people aged 18 years and above.

The EUL is granted for the vaccine produced and commercialised by SII under the brand name COVOVAX in India as well as licenced regions.

In September this year, the companies filed an application seeking WHO EUL for the vaccine.

Currently, another EUL submission by Novavax is being reviewed by the WHO for the vaccine intended to be sold as Nuvaxovid.

Novavax president and CEO Stanley Erck said: “Today’s decision from the World Health Organization is vital to ensuring global access to a protein-based Covid-19 vaccine for hundreds of millions of people around the world.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We believe this vaccine will help overcome barriers to vaccine access in many regions of the world by leveraging the traditional refrigeration used in existing vaccine supply channels, while also offering an option based on a familiar and well-understood technology.”

The authorisation is based on the totality of preclinical, manufacturing and trial data submitted to the WHO.

This comprises results from two Phase III trials: PREVENT-19, which had nearly 30,000 subjects in the US and Mexico; and a UK trial that enrolled over 14,000 subjects.

Findings showed that the vaccine had a greater efficacy with a favourable safety and tolerability profile.

It obtained emergency use authorization (EUA) in the Philippines and Indonesia.

Novavax intends to file the comprehensive chemistry, manufacturing and controls (CMC) data package to the US Food and Drug Administration by this year-end.